Pidotimod promotes functional maturation of dendritic cells and displays adjuvant properties at the nasal mucosa level

International Immunopharmacology

Volumn 9, Issue 12, 2009, Pages 1366-1373

  Giagulli, Cinzia ^a   Noerder, Miriam ^b   Avolio, Manuela ^a   Becker, Pablo D ^b   Fiorentini, Simona ^a   Guzman, Carlos A ^b   Caruso, Arnaldo ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

Adjuvant; Dendritic cell maturation; Mucosal immune response; Pidotimod

Indexed keywords

CD83 ANTIGEN; CD86 ANTIGEN; HLA DR ANTIGEN; MONOCYTE CHEMOTACTIC PROTEIN 1; OVALBUMIN; PIDOTIMOD; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; NORMAL HUMAN; NOSE MUCOSA; PRIORITY JOURNAL; SPLEEN CELL; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; ANTIGENS, CD; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CCL2; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; HLA-DR ANTIGENS; HUMANS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; NASAL MUCOSA; OVALBUMIN; PEPTIDE FRAGMENTS; PYRROLIDONECARBOXYLIC ACID; TH1 CELLS; THIAZOLIDINES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349426983     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2009.08.010     Document Type: Article

References (43)

1. Borghi M.O., Fain C., Barcellini W., Del Papa N., La Rosa L., Nicoletti F., Uslenghi C., and Meroni P.L. Ex vivo effect of pidotimod on peripheral blood mononuclear cell immune functions: study of an elderly population. Int J Immunotherapy 10 (1994) 35-39
2. Pugliese A., Uslenghi C., Torre D., D'Alonzo L., Corgnati F., and Girardello R. Evaluation of the effect of pidotimod on the in vitro production of interferons. Int J Immunotherapy 11 (1995) 71-76
3. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., Pulendran B., and Palucka K. Immunobiology of dendritic cells. Annu Rev Immunol 18 (2000) 767-811
4. Sallusto F., Cella M., Danieli C., and Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 182 (1995) 389-400
5. Reis C., Sousa, Stahl P.D., and Austyn J.M. Phagocytosis of antigens by Langerhans cells in vitro. J Exp Med 178 (1993) 509-519
6. Sheng K.C., Pietersz G.A., Wright M.D., and Apostolopoulos V. Dendritic cells: activation and maturation applications for cancer immunotherapy. Curr Med Chem 12 (2005) 1783-1800
7. Miller R.A. The ageing immune system: primer and prospectus. Science 273 (1996) 70-74
8. Yoshikawa T.T. Epidemiology and unique aspects of ageing and infectious diseases. Clin Infect Dis 30 (2000) 931-933
9. Murasco D.M., Bernstein E.D., Gardner E.M., Gross P., Munk G., Dran S., and Abrutyn E. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol 37 (2002) 427-439
10. Webster R.G. Immunity to influenza in the elderly. Vaccine 18 (2000) 1686-1689
11. Donnini A., Argentari K., Mancini R., Smorlesi A., Bartozzi B., Bernardini G., and Provinciali M. Phenotype, antigen-presenting capacity, and migration of antigen-presenting cells in young and old age. Exp Gerontol 37 (2002) 1097-1112
12. Gon Y., Hashimoto S., Hayashi S., Koura T., Matsumoto K., and Horie T. Lower serum concentrations of cytokines in elderly patients with pneumonia and the impaired production of cytokines by peripheral blood monocytes in the elderly. Clin Exp Immunol 106 (1996) 458-460
13. De Martinis M., Modesti M., and Ginaldi L. Phenotypic and functional changes of circulating monocytes and polymorphonuclear leukocytes from elderly persons. Immunol Cell Biol 82 (2004) 415-420
14. Rharbaoui F., Drabner B., Borsutzky S., Winckler U., Morr M., Ensoli B., Muhlradt P.F., and Guzman C.A. The mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. Eur J Immunol 32 (2002) 2857-2865
15. Becker P.D., Fiorentini S., Link C., Tosti G., Ebensen T., Caruso A., and Guzman C.A. The HIV-1 matrix protein p17 can be efficiently delivered by intranasal route in mice using the TLR 2/6 agonist MALP-2 as mucosal adjuvant. Vaccine 24 (2006) 5269-5276
16. Fiorentini S., Becker P.D., Marini E., Marconi P., Avolio M., Tosti G., Link C., Manservigi R., Guzman C.A., and Caruso A. HIV-1 matrix protein p17 modulates in vivo preactivated murine T-cell response and enhances the induction of systemic and mucosal immunity against intranasally co-administered antigens. Viral Immunol 19 (2006) 77-88
17. Coppi G., and Mailland F. Immunopharmacological studies on PGT/1A, a new immunostimulating drug. Pharmacol Res 22 (1990) 126-128
18. Migliorati G., D'Adamio L., Coppi G., Nicoletti I., and Ricardi C. Pidotimod stimulates natural killer cell activity and inhibits thymocyte cell death. Immunopharmacol Immunotoxicol 14 (1992) 737-748
19. Marelli P., Lupetti A., Senesi S., Uslenghi C., Girardello R., and Campa M. Potenziamento della resistenza alle infezioni virali e batteriche dopo somministrazione di Pidotimod nel topo. Drugs Exp Clin Res 19 (1993) 15-21
20. Careddu P., Biolchini A., Alfano S., and Zavattini G. Pidotimod in the prophylaxis of recurrent acute tonsillitis in childhood. Adv Otorhinolaryngol 47 (1992) 328-331
21. Careddu P. Role of immunoactivation with pidotimod in recurrent respiratory infections in childhood. Arzneimittelforschung/Drug Res 44 (1994) 1506-1511
22. Aivazis V., Hatzimichail A., Papachristou A., Valeri R., and Iuga-Donca G. Clinical evaluation and changes of the respiratory epithelium function after administration of pidotimod in Greek children with recurrent respiratory tract infections. Minerva Pediatr 54 (2002) 315-319
23. Hermans I.F., Silk J.D., Yang J., Palmowski M.J., Gileadi U., McCarthy C., Salio M., Ronchese F., and Cerundolo V. The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. J Immunol Methods 285 (2004) 25-40
24. Becker P.D., Nörder M., Guzmán C.A., and Grinstein S. Immune modulator adamantylamide dipeptide stimulates efficient major histocompatibility complex class I-restricted responses in mice. Clin Vaccine Immunol 14 5 (2007 May) 538-543
25. Snijders A., Kalinski P., Hilkens C.M., and Kapsenberg M.L. High-level IL-12 production by human dendritic cells requires two signals. Int Immunol 10 11 (1998 Nov) 1593-1598
26. Frasca L., Nasso M., Spensieri F., Fedele G., Palazzo R., Malavasi F., and Ausiello C.M. IFN-gamma arms human dendritic cells to perform multiple effector functions. J Immunol 180 3 (2008 Feb 1) 1471-1481
27. Jahnsen F.L., Gran E., Have R., and Brandtzaeg P. Human nasal mucosa contains antigen-presenting cells of strikingly different functional phenotypes. Am J Respir Cell Mol Biol 30 (2004) 31-37
28. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
29. Shortman K., and Liu Y.J. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2 (2002) 151-161
30. Manz R.A., and Radbruch A. Plasma cell for a lifetime?. Eur J Immunol 32 (2002) 923-927
31. Moser K., Tokoyoda K., Radbruk A., MacLennan I., and Manz R.A. Stromal niches, plasma cell differentiation and survival. Curr Opin Immunol 18 (2006) 265-267
32. Masihi K.N. Immunomodulators in infectious disease: panoply of possibilities. Int J Immunopharmacol 22 (2000) 1083-1091
33. Daly C., and Rollins B.J. Monocyte chemoattractant protein-1 (CCL2) in inflammatory disease and adaptive immunity: therapeutic opportunities and controversies. Microcirculation 10 (2003) 247-257 Review
34. Gu L., Rutledge B., Fiorillo J., Ernst C., Grewal I., Flavell R., Gladue R., and Rollins B. In vivo properties of monocyte chemoattractant protein-1. J Leukoc Biol 62 (1997) 577-580
35. Carr M.W., Roth S.J., Luther E., Rose S.S., and Springer T.A. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci U S A 91 (1994) 3652-3656
36. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 13 (1995) 251-276
37. Kadowaki N., Antonenko S., Lau J.Y., and Liu Y.J. Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J Exp Med 192 (2000) 219-226
38. De Jong E.C., Vieira P.L., Kalinski P., Schuitemaker J.H., Tanaka Y., Wierenga E.A., Yazdanbakhsh M., and Kapsenberg M.L. Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse Th cell-polarizing signals. J Immunol 168 4 (2002 Feb 15) 1704-1709
39. De Jong E.C., Vieira P.L., Kalinski P., Schuitemaker J.H., Tanaka Y., Wierenga E.A., Yazdanbakhsh M., and Kapsenberg M.L. Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse Th cell-polarizing signals. J Immunol 168 4 (2002 Feb 15) 1704-1709
40. Schijns V.E., Haagmans B.L., Wierda C.M., Kruithof B., Heijnen I.A., Alber G., and Horzinek M.C. Mice lacking IL-12 develop polarized Th1 cells during viral infection. J Immunol 160 (1998) 3958
41. Hoene V., Peiser M., and Wanner R. Human monocyte-derived dendritic cells express TLR9 and react directly to the CpG-A oligonucleotide D19. J Leukoc Biol 80 6 (2006 Dec) 1328-1336
42. Viola A., and Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science 273 (1996) 104-106
43. Yuan Q., and Walker W.A. Innate immunity of the gut: mucosal defense in health and disease. J Pediatr Gastroenterol Nutr 38 (2004) 463-473